ArticleTheranostics2021
Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 16 citations in OpenAlex.
- Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs . immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study.Chinese medical journal · 2026Article
- Immunological consequences of chemotherapy: implications for cancer immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Risk stratification of PD-L1 expression in non-small cell lung cancer: a predictive model for prognosis.Journal of thoracic disease · 2026Article
- Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.Frontiers in immunology · 2026Review
- Clinical features as prognostic markers in patients with solid tumors treated with programmed cell death protein 1/programmed cell death-ligand 1 inhibitors: a retrospective cohort study.Translational cancer research · 2025Article
- Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy.Translational lung cancer research · 2025Review
- A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014-2024).Frontiers in oncology · 2025Article
- LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features.Nature cancer · 2024Article
- Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.ESMO open · 2024Observational
- Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.Frontiers in immunology · 2023Review
- Article
- A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I-IIIA non-small cell lung cancer after resection.Annals of translational medicine · 2022Article
- SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.Frontiers in immunology · 2022Article
- Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC.International journal of biological sciences · 2022Article
- Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.Journal of immunology research · 2022Article
- Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.Frontiers in oncology · 2021Article
- Assessing tumor heterogeneity and FLOT/FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Yayi HeDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Linsong ChenDepartment of Surgery, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Lishu ZhaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Shiying DangHaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District, Shenzhen 518057, Guangdong, China.
Guifeng LiuHaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District, Shenzhen 518057, Guangdong, China.
Shinji SasadaDepartment of Respiratory Medicine, Tokyo Saiseikai Central Hospital, Minato-ku, Tokyo, Japan.
Patrick C MaPenn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USA.
Nico van ZandwijkSydney Local Health District, Concord Repatriation General Hospital, Concord, NSW, The University of Sydney, Australia.
Rafael RosellCancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra. Canyet, Badalona (Barcelona), Spain.
Helmut H PopperDepartment of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, Graz 8036, Austria.
Hao WangDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Minlin JiangDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Haoyue GuoDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Xinyi LiuHaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District, Shenzhen 518057, Guangdong, China.
Shifu ChenHaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District, Shenzhen 518057, Guangdong, China.
Xiaoni ZhangHaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District, Shenzhen 518057, Guangdong, China.
Mingyan XuHaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District, Shenzhen 518057, Guangdong, China.
Bo ZhuInstitute of Cancer, Xinqiao Hospital, the Army Medical University, No. 83, Xinqiaozheng Street, Shapingba District, Chongqing 400037, China.
Ming LiuDepartment of Surgery, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Caicun ZhouDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zhengmin Road, Yangpu District, Shanghai 200433, China.
Penn State Milton S. Hershey Medical Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
BiopsyCarcinoma, Non-Small-Cell LungEnzyme InhibitorsExome SequencingGene Expression ProfilingGene OntologyGenomicsHumansImmunotherapyINDEL MutationLung NeoplasmsObservational Studies as TopicProgrammed Cell Death 1 ReceptorProspective StudiesRNA-SeqSmokersEnzyme InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorchemotherapyimmunotherapyLung cancermessager ribonucleic acid (mRNA).programmed death-1 (PD-1)tumor mutational burden (TMB)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.